Senior Associate Scientist, Oncology

The Oncology group at Alnylam is seeking a highly motivated Senior Research Associate to join our team. As a highly focused interdisciplinary team we are seeking to bring the power of RNAi therapeutics to the fight against cancer. The successful candidate will be responsible for cell and molecular mechanism-based research efforts to evaluate therapeutic potential of biological targets and advance Alnylam's RNAi platform across multiple cancer indications. The ideal candidate will have a strong background in vitro cell culture, molecular and cellular techniques, and cancer related assays. The role requires ability to learn new techniques, capacity to multi-task, and willingness to collaborate with multiple interdisciplinary teams in a fast-paced environment.

This position is onsite and will be primarily located in Cambridge, MA.

Key Responsibilities

* Design, optimize, and execute cell and molecular based experiments to evaluate target biology and characterize the activity of developmental RNAi candidates in relevant oncology models.
* Design and optimize new assays and onboard new technologies to advance in vitro oncology efforts.
* Perform downstream processing and analysis from tissue samples and ex vivo models to support evaluation of target engagement, mechanism of action, and biomarker analysis of RNAi therapeutics.
* Analyze, interpret, and present research findings within a multidisciplinary Oncology team and to the wider organization to facilitate cross-functional collaboration.
* Excellent documentation practices in maintaining electronic lab notebook entries, protocols, data summaries, and technical reports.

Qualifications

* BS/MS in Biology, Biochemistry, Cancer Biology, or related field with 3-5 years experience in industry.
* Proficiency in molecular and cellular techniques including RT-qPCR, Western Blot, immunofluorescence and flow cytometry.
* Experience with cancer-relevant assays to measure cell proliferation, death, invasion, migration with live cell imaging systems (Sartorius Incucyte) is highly preferred.
* Excellent cell culture skills using nucleic acid-based approaches (such as RNAi, CRISPR, mRNA).
* Ability to optimize and perform experiments and summarize results with limited guidance.
* Must be a team player with good interpersonal skills, open to new tasks and challenges in a fast-paced environment.

About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.